This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G11.2 | Special Copayment Reduction: V123 |
| B. Synonyms | Late-onset cerebellar ataxia (onset usually after age 20), spinocerebellar ataxia (SCA) |
| C. Adult onset | High likelihood of first onset in adulthood — mostly onset in adulthood (20s~50s) |
| 1. History | ADCA classification by Harding 1982, molecular genetic identification of SCA1/2/3/6/7 etc. since the 1990s, SCA27B in 2023 |
| 2. Causes | More than 50 types, including SCA1 (ATXN1), SCA2 (ATXN2), SCA3 (ATXN3), SCA6 (CACNA1A), SCA7 (ATXN7) and SCA27B (FGF14) |
| 3. Genetics | Mostly autosomal dominant, CAG repeat expansion (SCA1/2/3/6/7/17) or other repeats and point mutations, anticipation |
| 4. General epidemiology | Overall SCA prevalence about 1~5/100,000; SCA3 (Machado-Joseph) the most common worldwide; SCA2 and SCA3 also common in Asia |
| 5. Pathophysiology | Polyglutamine toxicity (SCA1/2/3/7), calcium channel dysfunction (SCA6), FGF14 loss of function (SCA27B); diverse mechanisms |
| 6. Symptoms | Progressive cerebellar ataxia + subtype-specific symptoms: macular degeneration (SCA7), ophthalmoplegia (SCA3), episodic (SCA6) |
| 7. Signs | Gait and limb ataxia, eye movement abnormalities, dysarthria, subtype-specific pyramidal, extrapyramidal and peripheral nerve signs |
| 8. Screening | SCA gene panel testing after confirming family history; sequential testing prioritizing common subtypes |
| 9. Diagnosis | Repeat number analysis for each SCA gene, brain MRI (pattern of cerebellar and brainstem atrophy), SARA and ICARS clinical rating scales |
| 10. Treatment | Mainly symptomatic treatment (rehabilitation, acetazolamide and 4AP, riluzole); 4-aminopyridine effective for SCA27B; gene therapy clinical trials |
| 11. Prognosis | Progressive; loss of ambulation decades after onset; onset in children may be earlier due to anticipation |
| 12. Prevention | Prevention of transmission through genetic counseling, predictive genetic testing, PGT-M and prenatal diagnosis |
| 13. References | Klockgether T et al. Nat Rev Dis Primers 2019 and 9 other papers |
The history of the classification of late-onset cerebellar ataxia, that is, spinocerebellar ataxia (SCA), begins in the early 20th century. After Pierre Marie described 'spastic cerebellar ataxia' in 1893, various familial ataxias were mixed into this category, and confusion continued. In 1982, Anita Harding classified autosomal dominant cerebellar ataxia (ADCA) into types I, II and III based on clinical features, laying the foundation for clinical classification.
With advances in molecular genetics, individual genotypes began to be identified from the 1990s. SCA1 (ATXN1 CAG expansion) in 1993, SCA2 (ATXN2) in 1994, SCA3/Machado-Joseph disease (ATXN3) in 1994, SCA6 (CACNA1A) in 1997, SCA7 (ATXN7) in 1997, etc. were discovered in succession. Currently more than 50 SCA genotypes are registered, and the numbering (SCA1, SCA2...) follows the order of discovery.
In 2023, GAA repeat expansion in the FGF14 gene (SCA27B) was shown to be one of the most common causes of late-onset cerebellar ataxia, greatly changing the diagnostic system. SCA27B is characterized by downbeat nystagmus and episodic symptoms, and is known to be a treatable form that responds to 4-aminopyridine (4-AP).
More than 50 SCA genotypes have been identified as causes of late-onset cerebellar ataxia. The most important genotypes, classified by pathogenic mechanism, are as follows.
Polyglutamine (polyQ) expansion group: SCA1 (ATXN1), SCA2 (ATXN2), SCA3 (ATXN3/Machado-Joseph disease), SCA6 (CACNA1A), SCA7 (ATXN7), SCA17 (TBP). The CAG repeat number of each gene expands beyond a certain threshold, forming toxic polyglutamine proteins. Noncoding repeat expansion group: SCA8 (ATXN8OS/ATXN8), SCA10 (ATXN10), SCA12 (PPP2R2B), SCA27B (FGF14). Other point mutation or small deletion/duplication group: SCA5, SCA11, SCA13, SCA14, etc. SCA6 develops even with a relatively small expansion of the CAG repeat number in the CACNA1A gene (19~33 repeats) and is characterized by episodic symptoms.
SCA27B (FGF14 GAA expansion) is caused by expansion of the GAA repeat in intron 1 of the FGF14 gene to 250 or more repeats, and recent studies have shown it to emerge as the most common cause, accounting for 15~25% of patients with late-onset cerebellar ataxia. The FGF14 protein is involved in regulating inactivation of voltage-gated sodium channels (Nav), and its deficiency disrupts the normal firing pattern of cerebellar Purkinje cells.
Most late-onset cerebellar ataxias follow an autosomal dominant inheritance pattern. A single pathogenic allele is sufficient to cause disease, and 50% of a patient's children inherit the pathogenic allele. Genetic anticipation is prominent in SCA1/2/3/7, and the increase in CAG repeat number is particularly marked with paternal transmission, so earlier onset and faster progression may appear in children.
The CAG repeat diagnostic criteria differ by SCA subtype. The pathogenic range is 39 or more for SCA1, 33 or more for SCA2, 60 or more for SCA3, 19 or more for SCA6 and 37 or more for SCA7. SCA17 (TBP) is pathogenic at 46 or more, in which case a Huntington disease-like phenotype may appear. For SCA27B, the diagnostic criterion is 250 or more GAA repeats, and the disease develops with autosomal dominant inheritance (heterozygous).
De novo mutations or CAG repeat expansions may also be identified in patients with sporadic cerebellar ataxia. SCA gene panel testing contributes to diagnosis even in adult-onset ataxia without a family history. Clinical exome sequencing is used for further diagnosis when testing for known repeat expansions is negative.
The overall prevalence of spinocerebellar ataxia is estimated at about 1~5/100,000. The most common subtype differs by region: SCA3 (Machado-Joseph disease) is the most common SCA worldwide, with particularly high frequency in people of Portuguese descent, residents of the Azores and East Asia. SCA2 shows a very high founder-effect prevalence in Cuba. SCA6 is relatively common in Europe and Japan.
In Korea, SCA3 and SCA2 are relatively frequently reported, and SCA6 is also not uncommonly diagnosed. The total number of SCA patients in Korea is estimated at several hundred. With increased awareness since 2023, SCA27B is being newly diagnosed in many patients with late-onset sporadic and familial ataxia. The age of onset differs by subtype but is mostly in adulthood (20s~50s), and onset after the 50s is common in SCA6. The male-to-female ratio is generally equal.
The pathogenesis of SCA varies by subtype. In the polyglutamine expansion group (SCA1/2/3/7), proteins with expanded polyQ form intranuclear inclusions and interfere with transcription factors, chaperones and proteasomes, disrupting neuronal function. In SCA3, polyQ expansion of ataxin-3 causes selective neuronal damage in the cerebellar dentate nucleus, brainstem nuclei and spinal cord. In SCA1, nuclear accumulation of ataxin-1 interferes with interactions with RNA-binding proteins such as RBM17, causing abnormal RNA splicing.
In SCA6, a small CAG expansion in the P/Q-type voltage-gated calcium channel (Cav2.1), the product of the CACNA1A gene, causes channel dysfunction and disruption of calcium homeostasis in cerebellar Purkinje cells. Because SCA6 develops with a relatively mild polyQ expansion, other mechanisms are thought to be involved as well. In SCA27B (FGF14 GAA expansion), FGF14 protein expression is reduced, causing abnormal regulation of Na+ channel function in cerebellar Purkinje cells, which leads to disrupted firing patterns and abnormal cerebellar output. FGF14 deficiency causes excessive inactivation of voltage-gated sodium channels (Nav1.6), and 4-aminopyridine, which reverses this, is effective in improving SCA27B symptoms.
The symptom common to all SCA subtypes is progressive cerebellar ataxia. Gait instability, balance impairment, upper limb incoordination and dysarthria are the main symptoms, mostly beginning gradually in adulthood and worsening over decades. SCA-specific symptoms provide important clues for distinguishing subtypes.
In SCA1, in addition to cerebellar ataxia, pyramidal symptoms (spasticity, hyperreflexia), eye movement abnormalities (slow pursuit) and dysarthria are prominent. SCA2 is very characteristically associated with slow saccades, with peripheral neuropathy and, rarely, parkinsonism. SCA3 (Machado-Joseph disease) is characterized by cerebellar ataxia + spasticity or dystonia + peripheral neuropathy + eyelid retraction. SCA6 is a pure cerebellar ataxia with onset after middle age that progresses relatively slowly and may be accompanied by episodic dizziness and diplopia. SCA7 is a very characteristic subtype in which progressive macular degeneration and color vision impairment accompany cerebellar ataxia. SCA27B is characterized by downbeat nystagmus, episodic dizziness and gait ataxia and responds to 4-aminopyridine.
On neurological examination, the cerebellar signs common to SCA include wide-based gait, dysmetria, intention tremor, dysarthria and saccadic abnormalities. Cerebellar ataxia rating scales (SARA: Scale for the Assessment and Rating of Ataxia, ICARS: International Cooperative Ataxia Rating Scale) are the standard clinical assessment tools.
Eye movement examination is very useful for differentiating subtypes. Markedly slow saccades in SCA2 are the most specific finding. SCA6 and SCA27B are characterized by downbeat nystagmus and gaze-evoked nystagmus. In SCA3, eyelid retraction and abnormal facial muscle movements appear. In SCA7, retinal macular degeneration and pigmentary abnormalities are observed on ophthalmic examination.
Pyramidal signs (spasticity, positive Babinski, hyperreflexia) are common in SCA1, SCA3 and SCA8 and rare in SCA6. Peripheral neuropathy (hyporeflexia, sensory abnormalities) accompanies SCA2 and SCA3. Cognitive decline and parkinsonism appear in some SCA subtypes (some cases of SCA2 and SCA3). The pattern of cerebellar and brainstem atrophy on MRI differs somewhat by subtype.
It is important to suspect SCA and perform screening in patients with adult-onset progressive cerebellar ataxia. Checking the family history is the most basic step. When there is an autosomal dominant family history, molecular genetic testing for the common SCA subtypes (SCA1, SCA2, SCA3, SCA6, SCA7) is performed first. Testing priorities are set by looking for subtype-specific clinical clues (retinal degeneration in SCA7, slow saccades in SCA2, downbeat nystagmus in SCA27B, etc.).
Even in sporadic cases without a family history, there may be de novo or newly identified mutations such as SCA3, SCA6 and SCA27B, so gene panel testing is considered. SCA gene panels include CAG repeat expansion analysis (including SCA1/2/3/6/7/8/10/12/17) and, recently, FGF14 GAA repeat analysis as well. If negative, clinical exome sequencing is the next step.
Brain MRI is essential for assessing the pattern of cerebellar and brainstem atrophy and for excluding acquired causes (cerebral infarction, tumor, encephalitis, alcohol, vitamin deficiency, paraneoplastic syndrome, etc.). A paraneoplastic antibody panel (anti-Yo, anti-Hu, anti-Ri, etc.), vitamin E, B12 and thiamine levels, thyroid function and gluten antibody tests are performed to exclude acquired causes.
SCA is confirmed by molecular genetic testing analyzing the repeat number of the relevant gene. PCR-based fragment length analysis or repeat-primed PCR is the standard. For SCA27B, the GAA repeat number in intron 1 of the FGF14 gene is analyzed, with 250 or more being the pathogenic criterion. Even if negative, long-read sequencing is used for further diagnosis when clinical suspicion is strong.
The pattern of cerebellar atrophy on brain MRI supports the diagnosis. Atrophy of the anterior cerebellar lobe is prominent in SCA1, cerebellar-brainstem atrophy is marked in SCA2 and SCA3, and in SCA6 cerebellar atrophy appears relatively in isolation. MRI volumetry is used for monitoring progression. Ophthalmic examination and retinal electrophysiology are needed for diagnosis and follow-up of SCA7.
Quantitative clinical assessment using SARA or ICARS is used to measure the degree of progression and as a clinical trial endpoint. Nerve conduction studies are used to assess the presence of accompanying peripheral neuropathy. Quantifying saccade velocity, etc. with eye movement recording (eye movement tracking) helps in subtype differentiation and progression monitoring.
For most SCA subtypes there is currently no disease-modifying treatment, and symptom control is the main treatment goal. Rehabilitation therapy (physical, occupational and speech therapy) is fundamental for all subtypes, and regular cerebellar rehabilitation is most effective for maintaining function. Acetazolamide is effective in preventing episodic ataxia in SCA6. 4-Aminopyridine (4-AP) shows a significant effect in improving ataxia and nystagmus in SCA6 and SCA27B, and for SCA27B, 4-AP is the first-line treatment option.
Riluzole has been reported to have some effect in cerebellar ataxia in small randomized controlled studies, but results in large clinical studies are mixed. N-acetyl-leucine has recently drawn attention in clinical studies in hereditary cerebellar ataxias including SCA. Orthoses (AFO), walking aids and fall prevention programs are important for safety.
Research on gene-targeted therapy is in progress. In SCA3, suppression of ataxin-3 expression using mRNA antisense oligonucleotides (ASO) and AAV-based RNA interference (RNAi) therapy are showing positive results in preclinical studies. Similar gene-silencing strategies are being studied in SCA1, SCA2 and SCA7. Transcranial direct current stimulation (tDCS) of the cerebellum showed improvement in gait in small studies, but the level of evidence is still low.
SCA is a progressive neurodegenerative disease, and overall functional decline is inevitable. Age of onset and rate of progression vary with subtype and CAG repeat number. SCA3, SCA1 and SCA2 show relatively rapid progression, and patients may become unable to walk within 10~20 years of onset. SCA6 progresses slowly and, as a pure cerebellar form, allows long-term survival. SCA27B shows relatively slow progression in forms where episodic attacks predominate.
Due to anticipation, earlier onset and faster progression may appear in the children of patients, and this must be clearly explained in genetic counseling. In SCA7, vision loss due to retinal degeneration contributes independently to functional decline. In SCA3, quality of life declines more severely when spasticity and dyskinesia are present. Active rehabilitation therapy and prevention of complications contribute to prolonging the period of maintained function. Early integration of psychosocial support and palliative care is recommended.
Because SCA is autosomal dominant, 50% of a patient's children carry the pathogenic allele. Predictive genetic testing can be used to confirm risk before symptom onset, but as with Huntington disease, it must be performed within a rigorous framework of genetic counseling and psychological support. Through preimplantation genetic testing (PGT-M), transmission to children can be prevented by transferring only embryos that do not carry the pathogenic allele.
Prenatal diagnosis is also possible, by genetic analysis of fetal DNA obtained through chorionic villus sampling or amniocentesis. For at-risk individuals who do not wish to undergo predictive testing, there is also the method of nondisclosing linkage analysis (exclusion testing). Presymptomatic testing of minors is in principle not recommended unless there is a medical benefit.
In terms of secondary prevention, fall prevention, regular rehabilitation exercise and, in SCA7 patients, protection of the retina through UV blocking contribute to the prevention of complications. Through regular multidisciplinary follow-up care, functional decline can be detected early and appropriate support and orthoses prescribed.